secwatch.observer — SEC 8-K summary
======================================

Issuer:     Omega Therapeutics, Inc. (—)
CIK:        0001850838
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0000950170-24-066746
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Omega Therapeutics CMO Yan Moore departs; appoints Kaan Certel as Chief Business Officer
--------------------------------------------------------------------------------

- CMO Yan Moore's employment terminated effective May 31, 2024; separation agreement with severance per employment agreement.
- Company expects seamless continuation of Phase 1/2 trial for OTX-2002 (hepatocellular carcinoma); search for successor underway.
- Appointed Kaan Certel, Ph.D. as Chief Business Officer effective May 28, 2024; over 20 years of biopharma experience.
- Dr. Certel to lead global business development and strategic partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024066746/0000950170-24-066746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024066746/omga-20240528.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-066746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer